title: Facial diplegia after pembrolizumab treatment.
authors.affiliation: Department of Neurology, Mayo Clinic, Rochester, Minnesota, 55905, USA.
authors.forename: Micah D
authors.identifier: 0000-0002-0415-1944
authors.initials: MD
authors.lastname: Yost
authors.affiliation: Department of Neurology, Mayo Clinic, Rochester, Minnesota, 55905, USA.
authors.forename: Claudia Z
authors.initials: CZ
authors.lastname: Chou
authors.affiliation: Department of Neurology, Mayo Clinic, Rochester, Minnesota, 55905, USA.
authors.forename: Hugo
authors.initials: H
authors.lastname: Botha
authors.affiliation: Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: Matthew S
authors.initials: MS
authors.lastname: Block
authors.affiliation: Department of Neurology, Mayo Clinic, Rochester, Minnesota, 55905, USA.
authors.forename: Teerin
authors.initials: T
authors.lastname: Liewluck
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects*; D005158:Facial Paralysis / Q000139:chemically induced* / Q000000981:diagnostic imaging*; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; C582435:pembrolizumab